LivaNova PLC (LIVN)
LivaNova Expands OSA Care With FDA-Approved aura6000 System
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
Down 7.2% in 4 Weeks, Here's Why You Should You Buy the Dip in LivaNova (LIVN)
The heavy selling pressure might have exhausted for LivaNova (LIVN) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy
LivaNova (LIVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
LivaNova PLC (LIVN) Q4 2025 Earnings Call Transcript
LivaNova (LIVN) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for LivaNova (LIVN) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.8 per share. This compares to earnings of $0.81 per share a year ago.
LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates
LivaNova (LIVN) came out with quarterly earnings of $1.11 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.9 per share a year ago.
Is LivaNova (LIVN) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LivaNova: Robust Fundamentals, Long-Term Growth Potential
LivaNova remains a 'BUY' with a raised price target of $61/share, reflecting strong recent results and long-term growth potential. LIVN delivered double-digit revenue growth, improved margins, and raised guidance, driven by Cardiopulmonary and Neuromodulation segment performance. Despite a 20% short-term return, I see further upside due to robust fundamentals, market expansion, and clinical milestones supporting the investment thesis.
Should Value Investors Buy LivaNova (LIVN) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
LivaNova PLC (LIVN) Q2 2025 Earnings Call Transcript
LivaNova PLC (NASDAQ:LIVN ) Q2 2025 Earnings Conference Call August 6, 2025 8:00 AM ET Company Participants Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Briana Gotlin - Vice President of Investor Relations Stephanie Bolton - President of Global Epilepsy Vladimir A. Makatsaria - CEO & Director Conference Call Participants Adam Carl Maeder - Piper Sandler & Co., Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division David Kenneth Rescott - Robert W.
